Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments that restore cognitive function. Co.'s lead asset, CY6463, is central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGc) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), Cognitive Impairment Associated with Schizophrenia (CIAS), and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS). CY6463 is the main of its CNS portfolio with ongoing clinical programs in ADv, CIAS, and MELAS. Co.'s CNS asset, CY3018, is intended to expand the potential of sGC simulation for the treatment of disorders of the CNS. The CYCN stock yearly return is shown above.
The yearly return on the CYCN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CYCN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|